西黄胶囊联合吉西他滨+顺铂在晚期肺鳞状细胞癌患者中的应用效果  

Application effect of Xihuang capsule combined with gemcitabine and cisplatin in patients with advanced lung squamous cell carcinoma

作　　者：周洪清 张红[1] 王利今 ZHOU Hongqing;ZHANG Hong;WANG Lijin(Department of Oncology,the First Hospital of Hu’nan University of Chinese Medicine,Changsha 410007,Hu’nan,China)

机构地区：[1]湖南中医药大学第一附属医院肿瘤科,长沙410007

出　　处：《癌症进展》2025年第2期174-177,共4页Oncology Progress

摘　　要：目的探究西黄胶囊联合吉西他滨+顺铂在晚期肺鳞状细胞癌患者中的应用效果。方法根据治疗方法的不同将83例晚期肺鳞状细胞癌患者分为联合组(n=43)和化疗组(n=40),化疗组患者采用吉西他滨+顺铂治疗,联合组患者采用西黄胶囊联合吉西他滨+顺铂治疗。比较两组患者的临床疗效、免疫功能(CD3^(+)、CD4^(+)、CD8^(+))、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)]水平及不良反应发生情况。结果联合组患者的总有效率高于化疗组,不良反应总发生率低于化疗组,差异均有统计学意义(P﹤0.05)。治疗后,联合组患者CD3^(+)、CD4^(+)水平均高于本组治疗前和化疗组,CD8^(+)水平低于本组治疗前和化疗组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CYFRA21-1、SCC-Ag水平均低于本组治疗前,联合组患者CYFRA21-1、SCC-Ag水平均低于化疗组,差异均有统计学意义(P﹤0.05)。结论西黄胶囊联合吉西他滨+顺铂能够提高晚期肺鳞状细胞癌患者的疗效,改善免疫功能,降低肿瘤标志物水平,减少不良反应。Objective To investigate the application effect of Xihuang capsule combined with gemcitabine and cisplatin in patients with advanced lung squamous cell carcinoma.Method A total of 83 patients with advanced lung squamous cell carcinoma were divided into combined group(n=43)and chemotherapy group(n=40)according to different treatment methods.Patients in chemotherapy group were treated with gemcitabine+cisplatin,and patients in combined group were treated with Xihuang capsule combined with gemcitabine^(+)cisplatin.The clinical efficacy,immune function(CD3^(+),CD4^(+),CD8^(+)),tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC-Ag)]levels and the incidence of adverse reactions of the two groups were compared.Result The total effective rate of combined group was higher than that of chemotherapy group,and the total incidence of adverse reactions was lower than that of chemotherapy group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in combined group were higher than those before treatment and chemotherapy group,and the level of CD8^(+)was lower than that before treatment and chemotherapy group,the differences were statistically significant(P<0.05).After treatment,the levels of CYFRA21-1 and SCC-Ag in two groups were lower than those before treatment,and the levels of CYFRA21-1 and SCC-Ag in combined group were lower than those in chemotherapy group,the differences were statistically significant(P<0.05).Conclusion Xihuang capsule combined with gemcitabine^(+)cisplatin can improve the efficacy and immune function of patients with advanced lung squamous cell carcinoma,reduce the levels of tumor markers and adverse reactions.

关 键 词：西黄胶囊 吉西他滨 顺铂 晚期肺鳞状细胞癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]